Physicians' Academy for Cardiovascular Education

Landmark trials with PCSK9 inhibitors

10' education - Dec. 10, 2018 - Ph. Gabriel Steg, MD - Paris, France

PCSK9 inhibitors: How do they work?

10' education - Dec. 4, 2018 - John Chapman - Paris, France

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD

Screening for high blood pressure globally

10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk

3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD

Lowering Lp(a) potently and safely with antisense technology

3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD

Physical activity: every step counts, for everybody

3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA

Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort

3' education - Nov. 15, 2018 - JoAnn Manson, MD

Practice-changing results on in-hospital treatment of acute decompensated HF

3' education - Nov. 15, 2018 - Larry Allen, MD

Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients

3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD

Not all fish oils are created equal: different compounds have different effects

3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.

Initiation of ARNI in patients with acute decompensated heart failure

3' education - Nov. 13, 2018 - Eric Velazquez, MD

Comprehensive US approach to stimulate physical activity should tackle obesity and improve health

3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA

It's too early for treatment withdrawal after recovery from dilated cardiomyopathy

3' education - Nov. 12, 2018 - Jane Wilcox, MD

New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment

3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA

Highly purified EPA reduces important ischemic events in hypertriglyceridemia

3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

Elevated BP before the age of 40 years associated with incident CVD events in middle age

Literature - Dec. 10, 2018 - Yano Y et al., - JAMA. 2018

Community-based data show that increasing categories of severity of hypertension according to the 2017 ACC/AHA BP Guidelines are associated with increasing risk of CVD events in middle age.

Landmark trials with PCSK9 inhibitors

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 10, 2018 - Ph. Gabriel Steg, MD - Paris, France
Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

PCSK9: Outcomes and trials in clinical perspective Prof. Steg summarizes the main results from recent clinical trials with PCSK9 inhibitors and presents some additional analyses in subgroups.

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

DOAC treatment safe and effective in AF despite multi-morbidity

Literature - Dec. 4, 2018 - Alexander KP et al. - American Heart Journal 2018

A post-hoc analysis of the ARISTOTLE trial showed safety and efficacy of apixaban compared to warfarin in AF patients aged 55 years or older with multi-morbidity.

ACC Expert Consensus Decision Pathway gives recommendations on use of novel anti-diabetes drugs

News - Dec. 4, 2018

Expert Consensus Decision Pathways are meant to complement guidelines and bridge remaining gaps in clinical guidance, in this case the use of SGLT2 inhibitors and GLP-1RAs to lower CV risk in T2DM.

Contribute to the 87th EAS congress: deadline abstract submission postponed

Dec. 4, 2018

The deadline for abstract submission for the 87th edition of the European Society of Atherosclerosis congress, held in Maastricht, The Netherlands, on May 26 - 29, 2019, has been postponed to December 11, 2018.

PCSK9 inhibitors: How do they work?

PCSK9: Outcomes and trials in clinical perspective

10' education - Dec. 4, 2018 - John Chapman - Paris, France
Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

PCSK9: Outcomes and trials in clinical perspective Prof. Chapman explains the biology of PCSK9, its role in the regulation of LDL-R expression and the impact of a therapeutic approach with PCSK9 inhibitors.

Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension

10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK
Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

ESC 2018 Dr. Ajay Gupta investigated the long term effects of treatment with a calcium channel blocker-based regimen and a statin on mortality in patients with hypertension, and showed a legacy effect of the combined therapy.

Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation

AHA 2018 - Chicago, IL, USA

3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD
In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

AHA 2018 In the ANITSCHKOW study, patients with very high Lp(a) were treated with evolocumab 420 mg once monthly. The 14% lowering in Lp(a) was not sufficient to eliminate the inflammatory stimulans induced by Lp(a).

Epicardial fat in HFmrEF and HFpEF patients

News - Dec. 3, 2018

Patients with HF with LVEF >40% showed greater total epicardial fat content, which was not related to BMI. Epicardial fat volume was associated with the presence of AF and T2DM.

Age-associated BP rise may be a consequence of Western lifestyle rather than a natural process

Literature - Dec. 3, 2018 - Mueller NT et al. - JAMA Cardiol. 2018

A small cross-sectional study showed an age-associated rise in BP starting in childhood in a more Westernized community, compared to an isolated, non-acculturated community.

Sudden death is the most common cause of death after 30 days post-NSTE-ACS

Literature - Nov. 28, 2018 - Berg DD et al. - Eur Heart J 2018
In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.

In a population derived from 14 TIMI clinical trials, CV events caused the majority of deaths post-NSTE-ACS, with recurrent MI representing the most common cause of death within the first 30 days, and sudden death after the first 30 days.